Current clinical trials for the treatment of idiopathic pulmonary fibrosis: Invited review series

Respirology

Volumn 15, Issue 1, 2010, Pages 19-31

  Klingsberg, Ross C ^b   Mutsaers, Steven E ^c,d,e   Lasky, Joseph A ^a,b  

^a TULANE UNIVERSITY   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d Lung Institute of Western Australia   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antifibrotic; Clinical trial; Idiopathic pulmonary fibrosis; Therapy; Trial end point

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; ANTICOAGULANT AGENT; AZATHIOPRINE; BIBF 1120; BOSENTAN; CNTO 888; ENDOTHELIN A RECEPTOR ANTAGONIST; ETANERCEPT; FG 3019; GAMMA1B INTERFERON; GC 1008; IMATINIB; INTERLEUKIN 13 ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; MACITENTAN; MINOCYCLINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CCL2; OCTREOTIDE; PIRFENIDONE; PLACEBO; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; QAX 576; SILDENAFIL; TETRATHIOMOLYBDIC ACID; THALIDOMIDE; UNCLASSIFIED DRUG; UNIPROST; ZILEUTON;

AGE DISTRIBUTION; ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; HUMAN; HYPOXEMIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG FUNCTION; MONOTHERAPY; MUSCLE EXERCISE; NAUSEA; NONHUMAN; OXYGEN THERAPY; PALLIATIVE THERAPY; PATIENT CARE; PHYSIOTHERAPY; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; STOMACH FUNDOPLICATION; TERMINAL CARE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; TREATMENT FAILURE;

EID: 74049125611     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2009.01672.x     Document Type: Review

References (59)

1. Raghu G, Weycker D, Edelsberg J et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006 174 : 810 816.
2. Gribbin J, Hubbard RB, Le Jeune I et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006 61 : 980 985.
3. Iwai K, Mori T, Yamada N et al. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am. J. Resp. Crit. Care Med. 1994 150 : 670 675.
4. Spruit MA, Janssen DJA, Franssen FME et al. Rehabilitation and palliative care in lung fibrosis. Respirology 2009 14 : 781 787.
5. Martinez FJ, Safrin S, Weycker D et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann. Intern. Med. 2005 142 (12 Pt 1 963 967.
6. Hardie WD, Glasser SW, Hagood JS. Emerging concepts in the pathogenesis of lung fibrosis. Am. J. Pathol. 2009 175 : 3 16.
7. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008 294 : L152 60.
8. Kottmann RM, Hogan CM, Phipps RP et al. Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology 2009 14 : 917 933.
9. Collard HR, King TE, Bartelson BB et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003 168 : 538 542.
10. Raghu G, Brown KK, Bradford WZ et al. A placebo-controlled trial of interferon γ-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2004 350 : 125 133.
11. Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005 353 : 2229 2242.
12. Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Resp. Crit. Care Med. 2005 171 : 1040 1047.
13. Mannino DM, Reichert MM, Davis KJ. Lung function decline and outcomes in an adult population. Am. J. Respir. Crit. Care Med. 2006 173 : 985 990.
14. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 2000 161 (2 Pt 1 646 664.
15. Nadrous HF, Pellikka PA, Krowka MJ et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005 128 : 2393 2399.
16. Prasse A, Müller-Quernheim J. Non-invasive biomarkers in pulmonary fibrosis. Respirology 2009 14 : 788 795.
17. Prasse A, Probst C, Bargagli E et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009 179 : 717 723.
18. Figueira de Mello G, Carvalho CR, Kairalla RA et al. Small airway remodeling in idiopathic interstitial pneumonias: a pathological study. Respiration 2009 epub ahead of print).
19. Kinder BW, Brown KK, McCormack FX et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009 135 : 1557 1563.
20. Rogliani P, Mura M, Porretta MA et al. New perspectives in the treatment of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis. 2008 2 : 75 93.
21. Ziesche R, Hofbauer E, Wittmann K et al. A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 1999 341 : 1264 1269.
22. King TE, Albera C, Bradford WZ et al. Effect of interferon γ-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lance 2009 222 228.
23. Raghu G, Brown KK, Costabel U et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Resp. Crit. Care Med. 2008 178 : 948 955.
24. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. (Online) 2003 3 CD003134.
25. Walter N, Collard HR, King TE. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 2006 3 : 330 338.
26. Prior C, Haslam PL. In vivo levels and in vitro production of interferon-γ in fibrosing interstitial lung diseases. Clin. Exp. Immunol. 1992 88 : 280 287.
27. King TE. Interferon γ-1b for the treatment of idiopathic pulmonary fibrosis. N. Engl. J. Med. 2000 342 : 974 975.
28. Kim R, Meyer KC. Therapies for interstitial lung disease: past, present and future. Ther. Adv. Respir. Dis. 2008 2 : 319 338.
29. Oikonomou N, Harokopos V, Zalevksy J et al. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS ONE 2006 1 : e108.
30. Daniels CE, Wilkes MC, Edens M et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 2004 114 : 1308 1316.
31. Wang S, Wilkes MC, Leof EB et al. Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J. 2005 19 : 1 11.
32. Daniels CE, Wilkes MC, Edens M et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Investig. 2004 114 : 1308 1316.
33. Widmer N, Decosterd LA, Csajka C et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br. J. Clin. Pharmacol. 2006 62 : 97 112. (Pubitemid 44195246)
34. King TE, Behr J, Brown KK et al. BUILD-1: a randomised placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008 177 : 75 81.
35. Collard HR, Anstrom KJ, Schwarz MI et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007 131 : 897 899.
36. Meyer A, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J. 1994 7 : 431 436.
37. Willis BC, Liebler JM, Luby-Phelps K et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. 2005 166 : 1321 1332.
38. Rhyu DY, Yang Y, Ha H et al. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J. Am. Soc. Nephrol. 2005 16 : 667 675.
39. Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005 353 : 2285 2287.
40. Oku H, Shimizu T, Kawabata T et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 2008 590 : 400 408.
41. Hocher B, Schwarz A, Fagan KA et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am. J. Respir. Cell Mol. Biol. 2000 23 : 19 26.
42. Mutsaers SE, Marshall RP, Goldsack NR et al. Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm. Pharmacol. Ther. 1998 11 : 221 225.
43. Park SH, Saleh D, Giaid A et al. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med. 1997 156 (2 Pt 1 600 608.
44. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem. 1999 274 : 13729 13732.
45. Murray LA, Argentieri RL, Farrell FX et al. Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int. J. Biochem. Cell Biol. 2008 40 : 2174 2182.
46. Charbeneau RP, Peters-Golden M. Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin. Sci. 2005 108 : 479 491.
47. Lebtahi R, Moreau S, Marchand-Adam S et al. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J. Nucl. Med. 2006 47 : 1281 1287.
48. Kubo HN, Nakayama K, Yanai M et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005 128 : 1475 1482.
49. Brewer GJ, Morton S, Henrietta K. The use of copper-lowering therapy with tetrathiomolybdate in medicine. Expert Opin. Investig. Drugs 2009 18 : 89 97.
50. Raghu G, Freudenberger TD, Yang S et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur. Respir. J. 2006 27 : 136 142.
51. Raghu G, Yang ST, Spada C et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006 129 : 794 800.
52. Mageto Y, Flaherty K, Brown K et al. Safety and tolerability of human monoclonal antibody Fg-3019, anti-connective tissue growth factor, In patients with idiopathic pulmonary fibrosis. Chest 2004 126 : 773.
53. Nishiyama O, Kondoh Y, Kimura T et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008 13 : 394 399.
54. Horton MR, Danoff SK, Lechtzin N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax 2008 63 : 749.
55. Hope-Gill BD, Hilldrup S, Davies C et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003 168 : 995 1002.
56. Fujimoto K, Matsuzawa Y, Yamaguchi S et al. Benefits of oxygen on exercise performance and pulmonary hemodynamics in patients with COPD with mild hypoxemia. Chest 2002 122 : 457 463.
57. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 2000 161 (4 Pt 1 1172 1178.
58. Gilbert CR, Smith CM. Advanced lung disease: quality of life and role of palliative care. Mt Sinai J. Med. 2009 76 : 63 70.
59. Raghu G, IPFnet. Improving the standard of care for patients with idiopathic pulmonary fibrosis requires participation in clinical trials. Chest 2009 136 : 330 333.